Promoting targeted screening for Type 2 diabetes mellitus: The contribution of community pharmacists [1]

Diabetic Medicine

Volumn 22, Issue 6, 2005, Pages 812-813

  Simoens, S ^a   Foulon, E ^b   Dethier, M ^c   Mathieu, C ^a   Laekeman, G ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Royal Pharmaceutical Society of Limburg ^*

^c Royal Pharmaceutical Society of Limburg   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; HUMAN; HYPERTENSION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACIST; PHYSICIAN; PRIMARY MEDICAL CARE; RISK FACTOR; SCREENING;

EID: 20444393501     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01508.x     Document Type: Letter

References (6)

1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-950.
2. Egede LE, Simpson K. Epidemiology, treatment and costs of depression in adults with Type 2 diabetes. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 251-262.
3. CDC Diabetes Cost-effectiveness Study Group. The cost-effectiveness of screening for Type 2 diabetes. J Am Med Assoc 1998; 280: 1757-1763.
4. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for Type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140: 689-699.
5. Chen TH, Yen MF, Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 54 (Suppl. 1): S37-S42.
6. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type 2 diabetes. Diabetologia 2002; 45 (Suppl. 1): S13-S17.